Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 11
Submit an article Journal homepage
87
Views
1
CrossRef citations to date
0
Altmetric
Reviews

How could we have better vaccines against tuberculosis?

Pramod K Giri University of Notre Dame, Eck Center for Global Health & Infectious Disease, Department of Biological Sciences, IN-46556, Notre Dame, USA +1 574 339 7072; +1 574 631 7413; [email protected], [email protected]
, PhD
Pages 1759-1772 | Published online: 10 Oct 2008

Bibliography

  • World Health Organization. Global tuberculosis control: surveillance, planning financing. WHO/HTM/TB/2005. WHO Report 2005. Geneva, Switzerland
  • Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine 1999;17:915-22
  • Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45
  • Chennai, T. R. C. I. C. M. R. Fifteen year follow up of trial of BCG South India for tuberculosis prevention. Indian J Med Res 1999;110:56-69
  • Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 2004;291:2086-91
  • Hart PD. Efficacy and applicability of mass BCG. Vaccination in tuberculosis control. BMJ 1967;1:587-92
  • Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999;284:1520-3
  • Vordermeier HM, Cockle PC, Whelan A, et al. Development of diagnostic reagents to differentiate between Mycobacterium bovis BCG vaccination and M. bovis infection in cattle. Clin Diagn Lab Immunol 1999;6:675-82
  • Oettinger T, Jorgensen M, Ladefoged A, et al. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis 1999;79:243-50
  • Baily GV. Tuberculosis prevention Trial, Madras. Indian J Med Res 1980;72(Suppl l):1-74
  • Orme IM, Collins FM. Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Infect Immun 1984;44:28-32
  • Fine PE. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989;11(Suppl 2):S353-9
  • Flaherty DK, Vesosky B, Beamer GL, et al. Exposure to Mycobacterium avium can modulate established immunity against M. tuberculosis infection generated by Mycobacterium bovis BCG vaccination. J Leukoc Biol 2006;80:1262-71
  • Young SL, Slobbe L, Wilson R, et al. Environmental strains of Mycobacterium avium interfere with immune responses associated with Mycobacterium bovis BCG vaccination. Infect Immun 2007;75:2833-40
  • Elias D, Britton S, Aseffa A, et al. Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production. Vaccine 2008; In press
  • Elias D, Wolday D, Akuffo H, et al. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guerin (BCG) vaccination. Clin Exp Immunol 2001;123:219-25
  • Kaufamann SHE. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001;1:20-30
  • Gatafield J, Pieters J. Essential role for cholesterol in entry of mycobacteria into macrophages. Science 2000;288:1647-50
  • Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 1999;97:435-47
  • Manca C, Paul S, Barry CE, et al. Mycobacterium. tuberculosis catalase and peroxidase activities and resistance to oxidative killing in human monocytes in vitro. Infect Immun 1999;67:74-9
  • Schaible UE, Collins HL, Kaufman SHE. Confrontation between intracellular bacteria and the immune system. Adv Immunol 1999;71:267-377
  • McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxate shunt enzme isocitrate lyase. Nature 2000;406:735-8
  • Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun 1998;66:1277-81
  • Quesniaux V, Fremond C, Jacobs M, et al. Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infect 2004;6:946-59
  • Denis M. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell Immunol 1991;132:150-7
  • Gómez LM, Anaya JM, Vilchez JR, et al. A polymorphism in the inducible nitric oxide synthase gene is associated with tuberculosis. Tuberculosis (Edinb) 2007;87:288-94
  • Fenton MJ, Vermeulen MW. Immunopathology of tuberculosis: roles of macrophages and monocytes. Infect Immun 1996;64:683-90
  • Saunders BM, Cooper AM. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol 2000;78:334-41
  • Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008;20:443-9
  • Wolf AJ, Linas B, Trevejo-Nuñez GJ, et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007;179:2509-19
  • Brill KJ, Li Q, Barkin R, et al. Human natural killer cells mediated killing of intracellular Mycobacterium tuberculosis H37Rv granule-independent mechanism. Infect Immun 2001;69:1755-65
  • Pedrosa J, Saunders BM, Appelberg R, et al. Neutrophils play a protective role in systemic Mycobacterium tuberculosis infection in mice. Infect Immun 2000;68:577-83
  • Teitelbaum R, Schubert W, Gunther L, et al. The M cell as a portal of entry to the lung for the bacterial pathogen Mycobacterium tuberculosis. Immunity 1999;10:641-50
  • Means TK, Wang S, Lien E, et al. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999;163:3920-7
  • Bodnar KA, Serbina NV, Flynn JL. Fate of Mycobacterium tuberculosis within murine dendritic cells. Infect Immun 2001;69:800-9
  • Hertz CJ, Kiertscher SM, Godowski PJ, et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 2001;166:2444-50
  • Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988;334:395-402
  • Flesch IE, Kaufmann SH. Attempts to characterize the mechanisms involved in mycobacterial growth inhibition by gamma-interferon-activated bone marrow macrophages. Infect Immun 1988;56:1464-9
  • Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 1997;186:39-45
  • Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Ann Rev Immunol 2002;20:581-620
  • Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998;280:1432-5
  • Izzo AA, North RJ. Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus-Calmette-Guerin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. J Exp Med 1992;176:581-6
  • Tan JS, Canaday DH, Boom WH, et al. Human alveolar T lymphocyte responses to Mycobacterium tuberculosis antigens: role for CD4+ and CD8+ cytotoxic T cells and relative resistance of alveolar macrophages to lysis. J Immunol 1997;159:290-7
  • Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus (HIV) infection. N Engl J Med 1999;340:367-73
  • Rook GA, Hernandez-Pando R, Dheda K, Teng Seah G. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 2004;25:483-8
  • Buccheri S, Reljic R, Caccamo N, et al. IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice. Eur J Immunol 2007;37:729-37
  • Sugawara I, Yamada H, Mizuno S, Iwakura Y. IL-4 is required for defense against mycobacterial infection. Microbiol Immunol 2000;44:971-9
  • Rhodes SG, Graham SP. Is ‘timing’ important for cytokine polarization. Trends Immunol 2002;23:246-9
  • Khader S, Pearl J, Sakamoto K, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005;175:788-95
  • Khader S, Bell G, Pearl J, et al. IL-23 and IL-17 in establishment of protective pulmonary CD4+ T cell responses upon vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007;8:369-77
  • Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13:139-45
  • Umemura M, Yahagi A, Hamada S, et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007;178:3786-96
  • Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and nonself. Nat Immunol 2005;6:345-52
  • Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005;6:353-60
  • Guyot-Revol V, Innes JA, Hackforth S, et al. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Crit Care Med 2006;173:803-10
  • Hougardy JM, Place S, Hildebrand M, et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med 2007;176:409-16
  • Ribeiro-Rodrigues R, Resende Co T, Rojas R, et al. A role for CD4+ CD25+ T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 2006;144:25-34
  • Boussiotis VA, Tsai EY, Yunis EJ, et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000;105:1317-25
  • Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004;4:841-55
  • Chen X, Zhou B, Li M, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol 2007;123:50-9
  • Hougardy JM, Verscheure V, Locht C, Mascart F. In vitro expansion of CD4+CD25highFOXP3+CD127 low/-regulatory T cells from peripheral blood lymphocytes of healthy Mycobacterium tuberculosis-infected humans. Microbes Infect 2007;9:1325-32
  • Behar SM, Woodworth JS, Wu Y. Next generation: tuberculosis vaccines that elicit protective CD8+ T cells. Expert Rev Vaccines 2007;6:441-56
  • Flynn JL, Goldstein MM, Triebold KJ, et al. Major histocompatibility complex class I restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992;89:12013-7
  • Behar SM, Dascher CC, Grusby MJ, et al. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J Exp Med 1999;189:1973-80
  • Serbina NV, Flynn JL. Early emergence of CD8(+) T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis infected mice. Infect Immun 1999;67:3980-8
  • Stenger S, Mazzaccaro RJ, Uyemura K, et al. Differential effects of cytolytic T cell subsets on intracellular infection. Science 1997;276:1684-7.
  • Stenger S, Hanson DA, Teitelbaum R, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998;282:121-5
  • Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Ann Rev Immunol 2004;22:817-90
  • Beckman EM, Porcelli SA, Morita CT, et al. Recognition of a lipid antigen by CD1-restricted αβ+ T cells. Nature 1994;372:691-4
  • Dascher CC, Hiromatsu K, Xiong X, et al. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int Immunol 2003;15:915-25
  • Ulrichs T, Moody DB, Grant E, et al. T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect Immun 2003;71:3076-87
  • Boom WH. Gammadelta T cells and Mycobacterium tuberculosis. Microbes Infect 1999;1:187-95
  • Dieli F, Ivanyi J, Marsh P, et al. Characterization of lung gamma delta T cells following intranasal infection with Mycobacterium bovis bacillus Calmette-Guerin. J Immunol 2003;170:463-9
  • Boom WH, Chervenak KA, Mincek MA, Ellner JJ. Role of the mononuclear phagocyte as an antigen-presenting cell for human gamma delta T cells activated by live Mycobacterium tuberculosis. Infect Immun 1992;60:3480-8
  • Munk ME, Gatrill AJ, Schoel B, et al. Immunity to mycobacteria: possible role of alpha/beta and gamma/delta T lymphocytes. APMIS 1990;98:669-73
  • North RJ, Izzo AA. Granuloma formation in severe combined immunodeficient (SCID) mice in response to progressive BCG infection. Tendency not to form granulomas in the lung is associated with faster bacterial growth in this organ. Am J Pathol 1993;142:1959-66
  • Peng MY, Wang ZH, Yao CY, et al. Interleukin 17-producing gamma delta T cells increased in patients with active pulmonary tuberculosis. Cell Mol Immunol 2008;5:203-8
  • Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006;177:4662-9
  • Bosio CM, Gardner D, Elkins KL. Infection of B cell-deficient mice with CDC 1551, a clinical isolate of Mycobacterium tuberculosis: delay in dissemination and development of lung pathology. J Immunol 2000;164:6417-25
  • Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 1998;11:514-32
  • Pethe K, Alonso S, Biet F, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001;412:190-4
  • Williams A, Reljic R, Naylor I, et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 2004;111:328-33
  • Reljic R, Williams A, Ivanyi J. Mucosal immunotherapy of tuberculosis: is there a value in passive IgA? Tuberculosis (Edinb) 2006;86:179-90
  • Chambers MA, Wright DC, Brisker J, et al. A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome) protects guinea pigs from lethal tuberculosis. Vaccine 2004;22:1063-71
  • Hoft DF, Eickhoff CS. Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen. Infect Immun 2005;73:4934-40
  • Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006;4:469-76
  • Olsen AW, van Pinxteren LA, Okkeles LM, et al. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and ESAT-6. Infect Immun 2001;69:2773-8
  • Dietrich J, Aagaard C, Leah R, et al. Exchanging ESAT-6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT-6-based sensitive monitoring of vaccine efficacy. J Immunol 2005;17:6332-9
  • Skeiky YA, Alderson MR, Ovendale PJ, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004;172:7618-28
  • Evans JT, Ward JR, Kern J, Johnson ME. A single vaccination with protein-microspheres elicits a strong CD8 T cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4. Vaccine 2004;22:1964-72
  • Giri PK, Verma I, Khuller GK. Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration. FEMS Immunol Med Microbiol 2006;47:233-41
  • Rodriguez A, Troye-Blomberg M, Lindroth K, et al. B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues. Role of adjuvants and routes of immunization. Vaccine 2003;21:458-67
  • Brooks JV, FranK AA, Keen MA, et al. Boosting vaccine for tuberculosis. Infect Immun 2001;69:2714-7
  • Sable SB, Kalra M, Verma I, Khuller GK. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol 2007;122:239-51
  • Turner J, Rhoades ER, Keen M, et al. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000;68:1706-9
  • Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000;97:13853-8
  • Pym AS, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9:533-9
  • Hess J, Miko D, Catic A, et al. Mycobacterium bovis BCG strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 1998;95:5299-304
  • Moreira AL, Tsenova L, Murray PJ, et al. Aerosol infection of mice with recombinant BCG secreting murine IFN-gamma partially reconstitutes local protective immunity. Microb Pathog 2000;29:175-85
  • McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG- primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004;10:1240-4
  • Beveridge NE, Price DA, Casazza JP, et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007;37:3089-100
  • McShane H, Pathan AA, Sander CR, et al. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005;85:47-52
  • Hawkridge T, Scriba TJ, Gelderbloem S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008;198:544-52
  • Wang J, Thorson L, Stokes RW, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004;173:6357-65
  • Huygen K. DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis 1998;2:971-8
  • Lowrie DB, Tascon RE, Bonato VL, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999;400:269-71
  • Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 2006;5:803-25
  • Pinto R, Saunders BM, Camacho LR, et al. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing BCG vaccine. J Infect Dis 2004;1(89):105-12
  • Hinchey J, Lee S, Jeon BY, et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 2007;117:2279-88
  • Asensio JA, Arbués A, Pérez E, et al. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Expert Opin Biol Ther 2008;8:201-11
  • Smith DA, Parish T, Stoker NG, Bancrft GJ. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 2001;69:1142-50
  • Sambandamurthy VK, Derrick SC, Hsu T, et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 2006;24:6309-20
  • Brodin P, Majlessi L, Brosch R, et al. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. J Infect Dis 2004;190:115-22
  • Weiss DW. Vaccination against tuberculosis with nonliving vaccines. The problem and its historical background. Am Rev Respir Dis 1959;80:676-88
  • Chambers MA, Gavier-Widen D, Hewinson RG. Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge. FEMS Immunol Med Microbiol 2004;41:93-100
  • Holland SM. Cytokine therapy of mycobacterial infections. Adv Intern Med 2000;45:431-52
  • de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev 2003;(1):CD001166
  • Repique CJ, Li A, Collins FM, Morris SL. DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun 2002;70:3318-23
  • Cardona PJ, Amat I, Gordillo S, et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 2005;23:1393-8
  • Davis SS. Nasal vaccines. Adv Drug Deliv Rev 2001;51:21-42
  • Giri PK, Verma I, Khuller GK. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J Infect 2006;53:350-6
  • McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modifi ed vaccinia virus Ankara in humans. Nat Med 2003;9:729-35
  • Brooks JV, Frank AA, Keen MA, et al. Boosting vaccine for tuberculosis. Infect Immun 2001;69:2714-7
  • Mollenkopf HJ, Grode L, Mattow J, et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime–Rv3407 DNA boost vaccination against tuberculosis. Infect Immun 2004;72:6471-9
  • Brandt L, Skeiky YA, Alderson MR, et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 2004;72:6622-32
  • Goonetilleke NP, McShane H, Hannan CM, et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003;171:1602-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.